Zhao Yu, Qin Da, Li Xiangji, Wang Tiange, Zhang Tong, Rao Xiaosong, Min Li, Wan Zhiyi, Luo Chenghua, Xiao Mengmeng
Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, China.
Department of Retroperitoneal Tumor Surgery, International Hospital, Peking University, Beijing, China.
Discov Oncol. 2024 May 11;15(1):155. doi: 10.1007/s12672-024-01016-x.
Retroperitoneal liposarcoma (RPLS) is known for its propensity for local recurrence and short survival time. We aimed to identify a credible and specific prognostic biomarker for RPLS.
Cases from The Cancer Genome Atlas (TCGA) sarcoma dataset were included as the training group. Co-expression modules were constructed using weighted gene co-expression network analysis (WGCNA) to explore associations between modules and survival. Survival analysis of hub genes was performed using the Kaplan-Meier method. In addition, independent external validation was performed on a cohort of 135 Chinese RPLS patients from the REtroperitoneal SArcoma Registry (RESAR) study (NCT03838718).
A total of 19 co-expression modules were constructed based on the expression levels of 26,497 RNAs in the TCGA cohort. Among these modules, the green module exhibited a positive correlation with overall survival (OS, p = 0.10) and disease-free survival (DFS, p = 0.06). Gene set enrichment analysis showed that the green module was associated with endocytosis and soft-tissue sarcomas. Survival analysis demonstrated that NINJ1, a hub gene within the green module, was positively associated with OS (p = 0.019) in the TCGA cohort. Moreover, in the validation cohort, patients with higher NINJ1 expression levels displayed a higher probability of survival for both OS (p = 0.023) and DFS (p = 0.012). Multivariable Cox analysis further confirmed the independent prognostic significance of NINJ1.
We here provide a foundation for the establishment of a consensus prognostic biomarker for RPLS, which should not only facilitate medical treatment but also guide the development of novel targeted drugs.
腹膜后脂肪肉瘤(RPLS)以其局部复发倾向和较短生存时间而闻名。我们旨在确定一种可靠且特异的RPLS预后生物标志物。
来自癌症基因组图谱(TCGA)肉瘤数据集的病例被纳入训练组。使用加权基因共表达网络分析(WGCNA)构建共表达模块,以探索模块与生存之间的关联。使用Kaplan-Meier方法对枢纽基因进行生存分析。此外,对来自腹膜后肉瘤注册研究(RESAR)(NCT03838718)的135例中国RPLS患者队列进行了独立外部验证。
基于TCGA队列中26497个RNA的表达水平构建了总共19个共表达模块。在这些模块中,绿色模块与总生存(OS,p = 0.10)和无病生存(DFS,p = 0.06)呈正相关。基因集富集分析表明绿色模块与内吞作用和软组织肉瘤相关。生存分析表明,绿色模块内的枢纽基因NINJ1在TCGA队列中与OS呈正相关(p = 0.019)。此外,在验证队列中,NINJ1表达水平较高的患者在OS(p = 0.023)和DFS(p = 0.012)方面均显示出较高的生存概率。多变量Cox分析进一步证实了NINJ1的独立预后意义。
我们在此为建立RPLS的共识预后生物标志物提供了基础,这不仅应有助于医疗治疗,还应指导新型靶向药物研发。